Stoke Therapeutics, Inc. (STOK): Operating Cash Flow
$45.59M
Year ended 2025-12-31
-$177.99M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.59M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$86.85M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$81.07M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$31.87M | n/m | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | -$66.91M | n/m | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | -$42.22M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$31.05M | n/m | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | -$10.96M | n/a | 2020-03-23, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $45.59M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$57.57M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $10.24M | -13.8% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$115.67M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$8.58M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$166.78M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$322.98M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $6.73M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$35.69M | n/m |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗